<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473095</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 092-101</org_study_id>
    <nct_id>NCT01473095</nct_id>
  </id_info>
  <brief_title>Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to&#xD;
      subjects with advanced solid tumors and recurrent malignant lymphoma. The study is designed&#xD;
      to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to&#xD;
      define a recommended Phase 2 dose of ARQ 092.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">August 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of ARQ 092 in subjects with advanced solid tumors and recurrent malignant lymphoma by monitoring frequency and severity of adverse events</measure>
    <time_frame>Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetic profile (Cmax, AUC, and half-life) of ARQ 092</measure>
    <time_frame>During the first 29 days of treatment for each dose level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess pharmacodynamic activity</measure>
    <time_frame>During the first 29 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine preliminary evidence of activity as defined by RECIST v 1.1</measure>
    <time_frame>Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine recommended Phase 2 dose</measure>
    <time_frame>Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 to 16 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">120</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Malignant Lymphoma</condition>
  <condition>Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 092</intervention_name>
    <description>Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women ≥18 years old&#xD;
&#xD;
          2. Histologically or cytologically documented, incurable, locally advanced or metastatic&#xD;
             solid tumors or recurrent malignant lymphoma in subjects who failed standard therapy&#xD;
             or for whom standard or curative therapy does not exist or is not tolerable.&#xD;
&#xD;
          3. Evaluable or measurable disease&#xD;
&#xD;
          4. Life expectancy greater than three months&#xD;
&#xD;
          5. ECOG performance status ≤2&#xD;
&#xD;
          6. Hemoglobin (Hgb) ≥9.5 g/dl&#xD;
&#xD;
          7. Absolute neutrophil count (ANC) ≥1.5 x 10^9/L&#xD;
&#xD;
          8. Platelet count ≥75 x 10^9/L&#xD;
&#xD;
          9. Total bilirubin ≤1.5 × upper limit of normal (ULN)&#xD;
&#xD;
         10. Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 × ULN&#xD;
&#xD;
         11. Serum creatinine ≤1.5 x ULN or creatinine clearance &gt; 60 mL/min/1.73 m^2 for subjects&#xD;
             with creatinine levels &gt;1.5 x ULN&#xD;
&#xD;
         12. Agree to use double-barrier contraceptive measures or avoid intercourse during the&#xD;
             study and for 90 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of Type 1 or 2 diabetes mellitus requiring regular medication (other than&#xD;
             metformin or other oral hypoglycemic agents) or fasting glucose ≥160 mg/dL at the&#xD;
             prestudy visit. If a diabetic cohort is enrolled, only subjects with a medical history&#xD;
             of controlled Type 1 or 2 diabetes mellitus will be enrolled in the cohort.&#xD;
&#xD;
          2. Grade 2 or worse hypercholesterolemia or hypertriglyceridemia or &gt;8% glycated Hb&#xD;
             (HbA1C)&#xD;
&#xD;
          3. Malabsorption syndrome&#xD;
&#xD;
          4. Known brain metastases not radiographically stable for ≥3 months or leptomeningeal&#xD;
             disease&#xD;
&#xD;
          5. History of myocardial infarction (MI) or NYHA Class II-IV congestive heart failure&#xD;
             within 6 months of the administration of the first dose of ARQ 092 (MI occurring &gt;6&#xD;
             months of the first dose of ARQ 092 will be permitted); Grade 2 or worse conduction&#xD;
             defect (eg right or left bundle branch block); left ventricular ejection fraction&#xD;
             (LVEF) &lt; 50% assessed by echocardiogram/MUGA scan&#xD;
&#xD;
          6. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents&#xD;
             within four weeks of the first dose of ARQ 092 (within 2 weeks for orally administered&#xD;
             drugs)&#xD;
&#xD;
          7. Major surgery within four weeks of the first dose of ARQ 092&#xD;
&#xD;
          8. Previous treatment with AKT inhibitors&#xD;
&#xD;
          9. Concurrent severe uncontrolled illness not related to cancer&#xD;
&#xD;
         10. Ongoing or active known infection, including human immunodeficiency virus (HIV)&#xD;
             infection or bleeding&#xD;
&#xD;
         11. Psychiatric illness/substance abuse/social situation that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
         12. Blood transfusion within 5 days prior to blood draw being used to confirm eligibility&#xD;
&#xD;
         13. Pregnant or breastfeeding&#xD;
&#xD;
         14. Previous other malignancy within 2 years prior to the first dose of ARQ 092, with the&#xD;
             exception of carcinoma in-situ of the cervix, basal cell carcinoma and superficial&#xD;
             bladder tumors curatively treated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 10, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKT</keyword>
  <keyword>ARQ 092</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Molecular therapy</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Phase I</keyword>
  <keyword>Endometrial cancer</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>AKT pathway</keyword>
  <keyword>AKT signaling</keyword>
  <keyword>AKT inhibitor</keyword>
  <keyword>AKT pan inhibitor</keyword>
  <keyword>AKT1</keyword>
  <keyword>AKT2</keyword>
  <keyword>AKT3</keyword>
  <keyword>AKT1 mutation</keyword>
  <keyword>AKT1-E17K</keyword>
  <keyword>AKT1-E17K mutation</keyword>
  <keyword>AKT 2 inhibitor</keyword>
  <keyword>AKT 3 inhibitor</keyword>
  <keyword>AKT 3 amplification</keyword>
  <keyword>PI3K AKT mTOR signalling pathway</keyword>
  <keyword>mTOR inhibitor</keyword>
  <keyword>PI3K inhibitor</keyword>
  <keyword>Clinical oncology</keyword>
  <keyword>Tumor</keyword>
  <keyword>Tumour</keyword>
  <keyword>PIK3CA H1047R mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

